MiniMed 780G System Sensor Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2026
0mins
Source: Newsfilter
- Study Consistency: A randomized crossover study demonstrated that participants using the MiniMed™ 780G system showed nearly identical glycemic control metrics with the Simplera Sync™ and Instinct sensors, achieving time in range of 79.1% and 80.6% respectively, indicating that the intelligence of the algorithm is the primary determinant of clinical outcomes.
- Clinical Validation: The study reported no cases of diabetic ketoacidosis or severe hypoglycemia among the 24 adult participants with type 1 diabetes during the six-week sensor usage period, further validating the safety and efficacy of the MiniMed™ 780G system.
- Real-World Evidence: An analysis of over 20,000 U.S. users of the MiniMed™ 780G system showed that users maintained strong glycemic control after transitioning to the Instinct sensor, reinforcing the algorithm's central role in diabetes management.
- Future Development Focus: MiniMed CEO Que Dallara emphasized the company's commitment to advancing the science of automated insulin delivery and building a seamless insulin delivery ecosystem to simplify diabetes management and enhance user experience.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MMED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MMED
Wall Street analysts forecast MMED stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 11.510
Low
Averages
High
Current: 11.510
Low
Averages
High
About MMED
MiniMed Group, Inc. is a medical technology company, which develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Its fully integrated system addresses pain points for people with diabetes (PWD): health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system. The MiniMed 780G system uses its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings. The MiniMed 780G consists of the MiniMed 780G insulin pump, the Simplera Sync CGM sensor, and the instinct sensor. Its platform of clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and a Smart Multiple Daily Injection (MDI) System. Its pipeline products are the MiniMed Flex, screenless insulin pump, next-generation Vivera dosing algorithm, and MiniMed Fit patch pump with extended wear.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MiniMed Showcases New Technology at American Diabetes Association Conference
- Technology Showcase: MiniMed will present its latest MiniMed Go™ and MiniMed Flex™ systems at the American Diabetes Association Scientific Sessions from June 5-8, aiming to alleviate the daily burden on diabetes patients through advanced automation and more compact designs, thereby enhancing patients' quality of life.
- Clinical Data Release: The company will share emerging clinical data demonstrating the real-world impact of its connected solutions, particularly highlighting the effectiveness of its recently refreshed sensor portfolio in improving patient health outcomes.
- Interactive Experience: Attendees will have hands-on opportunities to explore the real-time SmartGuard™ automation features of the MiniMed Flex™ system and the memory, reminder, and recommendation capabilities of the MiniMed Go™ smart insulin pen, further enhancing user experience.
- Industry Leadership: As a global leader in insulin delivery, MiniMed continues to advance diabetes treatment technologies in 80 countries, committed to helping patients manage diabetes more easily through an integrated ecosystem and high-quality service, showcasing its innovation and influence in the industry.
See More
MiniMed Showcases New Technology at American Diabetes Association Conference
- Technology Showcase: MiniMed will present its latest MiniMed Go™ and MiniMed Flex™ systems at the American Diabetes Association's Scientific Sessions from June 5-8, aiming to alleviate the daily burden of diabetes through advanced automation and smaller designs, thereby enhancing the quality of life for patients.
- Clinical Data Release: The company will share emerging clinical data demonstrating the real-world impact of its connected solutions, particularly how the recently refreshed sensor portfolio improves blood glucose control, further solidifying MiniMed's leadership in diabetes technology.
- Interactive Experience: Attendees will have hands-on opportunities to explore the real-time SmartGuard™ automation of the MiniMed Flex™ system and the MiniMed Go™ smart insulin pen's memory, reminders, and recommendations, enhancing user understanding and acceptance of new technologies.
- Scientific Presentations: MiniMed will also showcase multiple posters covering the application effects of automated insulin delivery systems in diverse populations, emphasizing the sustained effectiveness of its 780G system in diabetes management, thereby furthering the company's influence in the healthcare sector.
See More
MiniMed to Participate in Goldman Sachs Healthcare Conference
- Goldman Sachs Conference Participation: MiniMed will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 8, 2026, which is expected to attract investor attention and enhance the company's visibility in the healthcare technology sector.
- Live Webcast and Replay: The fireside chat is scheduled for 11:20 a.m. EDT, and MiniMed will provide a live webcast and replay on its Investor Relations website, ensuring broad investor engagement and information transparency.
- Global Leadership Position: As a global leader in insulin delivery technology, MiniMed offers innovative therapies in over 80 countries, continuously improving the quality of life for diabetes patients and showcasing its strong influence in the healthcare technology industry.
- Mission and Vision: MiniMed is committed to simplifying diabetes management through an integrated ecosystem of insulin delivery systems, continuous glucose monitors, and user-friendly apps, reflecting the company's long-term dedication to improving patient lives.
See More
MiniMed 780G Study Results Highlight Algorithm's Role in Insulin Delivery
- Algorithm-Driven Outcomes: A randomized crossover study revealed that participants using the MiniMed™ 780G system with either the Simplera Sync™ or Instinct sensor achieved nearly identical glycemic control metrics, underscoring the algorithm's pivotal role in clinical outcomes and reinforcing the system's market position.
- Clinical Validation Data: The study demonstrated that time in range for participants was 79.1% with Instinct and 80.6% with Simplera Sync™, both exceeding the American Diabetes Association's international consensus targets, indicating the system's effectiveness and reliability in diabetes management.
- Real-World Evidence: Analysis of over 20,000 U.S. users of the MiniMed™ 780G system confirmed the algorithm's central role in maintaining strong glycemic control, further enhancing user confidence in the system's capabilities.
- Broad Market Prospects: MiniMed CEO Que Dallara emphasized the company's commitment to advancing the science of automated insulin delivery and building a comprehensive insulin delivery ecosystem, suggesting significant future market potential for diabetes management solutions.
See More
MiniMed 780G System Sensor Study Results
- Study Consistency: A randomized crossover study demonstrated that participants using the MiniMed™ 780G system showed nearly identical glycemic control metrics with the Simplera Sync™ and Instinct sensors, achieving time in range of 79.1% and 80.6% respectively, indicating that the intelligence of the algorithm is the primary determinant of clinical outcomes.
- Clinical Validation: The study reported no cases of diabetic ketoacidosis or severe hypoglycemia among the 24 adult participants with type 1 diabetes during the six-week sensor usage period, further validating the safety and efficacy of the MiniMed™ 780G system.
- Real-World Evidence: An analysis of over 20,000 U.S. users of the MiniMed™ 780G system showed that users maintained strong glycemic control after transitioning to the Instinct sensor, reinforcing the algorithm's central role in diabetes management.
- Future Development Focus: MiniMed CEO Que Dallara emphasized the company's commitment to advancing the science of automated insulin delivery and building a seamless insulin delivery ecosystem to simplify diabetes management and enhance user experience.
See More
Latest Wall Street Ratings Overview
- Goldman Sachs Bullish on Aevex: Goldman Sachs initiates coverage of Aevex (AVEX) with a Buy rating and a $34 price target, based on a 5.4X CY27 EV/Sales, indicating confidence in the company's unique position in the drone market and its growth potential.
- Citi Raises Broadcom Target: Citi raises Broadcom's price target from $475 to $500, applying a 20x multiple to FY28 EPS of $25, reflecting optimism about the company's earnings visibility and maintaining its status as the #1 semiconductor pick for 2026.
- JPMorgan Upgrades Braskem: JPMorgan upgrades Braskem to Overweight from Neutral, citing improved market fundamentals, tighter supply, and strengthened governance post-restructuring, which are expected to enhance profit margins in the chemical sector.
- Evercore Initiates Benitec Coverage: Evercore initiates coverage of Benitec Biopharma with an Overweight rating, highlighting significant upside potential in the rare disease market, suggesting promising investment opportunities ahead.
See More
MiniMed Showcases New Technology at American Diabetes Association Conference
- Technology Showcase: MiniMed will present its latest MiniMed Go™ and MiniMed Flex™ systems at the American Diabetes Association Scientific Sessions from June 5-8, aiming to alleviate the daily burden on diabetes patients through advanced automation and more compact designs, thereby enhancing patients' quality of life.
- Clinical Data Release: The company will share emerging clinical data demonstrating the real-world impact of its connected solutions, particularly highlighting the effectiveness of its recently refreshed sensor portfolio in improving patient health outcomes.
- Interactive Experience: Attendees will have hands-on opportunities to explore the real-time SmartGuard™ automation features of the MiniMed Flex™ system and the memory, reminder, and recommendation capabilities of the MiniMed Go™ smart insulin pen, further enhancing user experience.
- Industry Leadership: As a global leader in insulin delivery, MiniMed continues to advance diabetes treatment technologies in 80 countries, committed to helping patients manage diabetes more easily through an integrated ecosystem and high-quality service, showcasing its innovation and influence in the industry.
See More
MiniMed Showcases New Technology at American Diabetes Association Conference
- Technology Showcase: MiniMed will present its latest MiniMed Go™ and MiniMed Flex™ systems at the American Diabetes Association's Scientific Sessions from June 5-8, aiming to alleviate the daily burden of diabetes through advanced automation and smaller designs, thereby enhancing the quality of life for patients.
- Clinical Data Release: The company will share emerging clinical data demonstrating the real-world impact of its connected solutions, particularly how the recently refreshed sensor portfolio improves blood glucose control, further solidifying MiniMed's leadership in diabetes technology.
- Interactive Experience: Attendees will have hands-on opportunities to explore the real-time SmartGuard™ automation of the MiniMed Flex™ system and the MiniMed Go™ smart insulin pen's memory, reminders, and recommendations, enhancing user understanding and acceptance of new technologies.
- Scientific Presentations: MiniMed will also showcase multiple posters covering the application effects of automated insulin delivery systems in diverse populations, emphasizing the sustained effectiveness of its 780G system in diabetes management, thereby furthering the company's influence in the healthcare sector.
See More
MiniMed to Participate in Goldman Sachs Healthcare Conference
- Goldman Sachs Conference Participation: MiniMed will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 8, 2026, which is expected to attract investor attention and enhance the company's visibility in the healthcare technology sector.
- Live Webcast and Replay: The fireside chat is scheduled for 11:20 a.m. EDT, and MiniMed will provide a live webcast and replay on its Investor Relations website, ensuring broad investor engagement and information transparency.
- Global Leadership Position: As a global leader in insulin delivery technology, MiniMed offers innovative therapies in over 80 countries, continuously improving the quality of life for diabetes patients and showcasing its strong influence in the healthcare technology industry.
- Mission and Vision: MiniMed is committed to simplifying diabetes management through an integrated ecosystem of insulin delivery systems, continuous glucose monitors, and user-friendly apps, reflecting the company's long-term dedication to improving patient lives.
See More
MiniMed 780G Study Results Highlight Algorithm's Role in Insulin Delivery
- Algorithm-Driven Outcomes: A randomized crossover study revealed that participants using the MiniMed™ 780G system with either the Simplera Sync™ or Instinct sensor achieved nearly identical glycemic control metrics, underscoring the algorithm's pivotal role in clinical outcomes and reinforcing the system's market position.
- Clinical Validation Data: The study demonstrated that time in range for participants was 79.1% with Instinct and 80.6% with Simplera Sync™, both exceeding the American Diabetes Association's international consensus targets, indicating the system's effectiveness and reliability in diabetes management.
- Real-World Evidence: Analysis of over 20,000 U.S. users of the MiniMed™ 780G system confirmed the algorithm's central role in maintaining strong glycemic control, further enhancing user confidence in the system's capabilities.
- Broad Market Prospects: MiniMed CEO Que Dallara emphasized the company's commitment to advancing the science of automated insulin delivery and building a comprehensive insulin delivery ecosystem, suggesting significant future market potential for diabetes management solutions.
See More
MiniMed 780G System Sensor Study Results
- Study Consistency: A randomized crossover study demonstrated that participants using the MiniMed™ 780G system showed nearly identical glycemic control metrics with the Simplera Sync™ and Instinct sensors, achieving time in range of 79.1% and 80.6% respectively, indicating that the intelligence of the algorithm is the primary determinant of clinical outcomes.
- Clinical Validation: The study reported no cases of diabetic ketoacidosis or severe hypoglycemia among the 24 adult participants with type 1 diabetes during the six-week sensor usage period, further validating the safety and efficacy of the MiniMed™ 780G system.
- Real-World Evidence: An analysis of over 20,000 U.S. users of the MiniMed™ 780G system showed that users maintained strong glycemic control after transitioning to the Instinct sensor, reinforcing the algorithm's central role in diabetes management.
- Future Development Focus: MiniMed CEO Que Dallara emphasized the company's commitment to advancing the science of automated insulin delivery and building a seamless insulin delivery ecosystem to simplify diabetes management and enhance user experience.
See More
Latest Wall Street Ratings Overview
- Goldman Sachs Bullish on Aevex: Goldman Sachs initiates coverage of Aevex (AVEX) with a Buy rating and a $34 price target, based on a 5.4X CY27 EV/Sales, indicating confidence in the company's unique position in the drone market and its growth potential.
- Citi Raises Broadcom Target: Citi raises Broadcom's price target from $475 to $500, applying a 20x multiple to FY28 EPS of $25, reflecting optimism about the company's earnings visibility and maintaining its status as the #1 semiconductor pick for 2026.
- JPMorgan Upgrades Braskem: JPMorgan upgrades Braskem to Overweight from Neutral, citing improved market fundamentals, tighter supply, and strengthened governance post-restructuring, which are expected to enhance profit margins in the chemical sector.
- Evercore Initiates Benitec Coverage: Evercore initiates coverage of Benitec Biopharma with an Overweight rating, highlighting significant upside potential in the rare disease market, suggesting promising investment opportunities ahead.
See More
